• The Phase 3 clinical trials for DCCR—its sole commercial product intended to treat hyperphagia in individuals with Prader-Willi syndrome (PWS)—allegedly downplayed, misrepresented, or omitted significant evidence of safety concerns, including signs of excessive fluid retention in participants.
• As a result, the treatment may have posed greater safety risks than what the company disclosed publicly.
• Consequently, DCCR’s commercial prospects were potentially overstated, while risks such as adverse side effects, higher discontinuation rates, reduced patient uptake, physician hesitation, possible regulatory challenges, and reputational or legal consequences were not fully revealed.

Kahn Swick & Foti, LLC (KSF), along with its partner Charles C. Foti Jr., has alerted investors of Navan, Inc about a securities class action lawsuit filed against the company.

Class Definition
The legal action aims to recover losses for investors who purchased Navan shares through or traceable to the Registration Statement and Prospectus (together referred to as the “Offering Documents”) issued for the company’s October 2025 initial public offering (IPO). Individuals seeking additional details or wishing to speak with a member of the legal team can visit: https://www.ksfcounsel.com/cases/nasdaqgs-navn/

Navan investors may also reach out to KSF Managing Partner Lewis Kahn by calling 1-877-515-1850 or emailing lewis.kahn@ksfcounsel.com for further information about the case.

Case Details
The complaint alleges that Navan and certain company executives failed to disclose important information in the Offering Documents, potentially breaching federal securities laws. Specifically, the filing claims that the documents omitted or misrepresented key facts, including a substantial rise in the company’s “sales and marketing” expenses. For the quarter ending October 31, 2025, those costs reportedly climbed to nearly $95 million—an increase of about 39% compared with $68.5 million recorded in the quarter ending July 31, 2025. According to the lawsuit, once this information became public, Navan’s share price dropped significantly.

The case is titled McCown v. Navan, Inc., Case No. 26-cv-01550.

Next Steps for Investors
Investors who bought Navan securities during the relevant period and experienced financial losses have until April 24, 2026 to ask the court to appoint them as the lead plaintiff. Participation in any potential settlement or recovery, however, does not require serving in that role.

1. Its ability to effectively manage channel inventory levels.
2. Its capacity to mitigate the financial impact of the termination of the Residential Clean Energy Credit under Section 25D of the Internal Revenue Code.
3. The resulting effect on the company’s financial outlook and operational performance, which investors claim was overstated.

Allegations in the Case

1. ENTRA1 had no track record of building, financing, or operating major projects, particularly in the highly specialized nuclear energy sector.
2. NuScale committed substantial capital and entrusted commercialization, distribution, and deployment of its NPM technology to a partner lacking meaningful experience in nuclear facility ownership or operations.
3. The qualifications cited by defendants largely related to individuals associated with the Habboush Group—an entity separate from ENTRA1 and without notable nuclear energy expertise.
4. These factors exposed NuScale’s commercialization strategy to significant, undisclosed risks, including potential delays, regulatory hurdles, and project failures.

Lead Plaintiff Information